Related Experiment Video
Updated: Aug 11, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Prevalence, diagnosis, and treatment of hepatitis C in Mainland China
1Department of Severe Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Insights
Hepatitis C virus (HCV) infection in China affects 0.91% of the population, primarily transmitted via injected drugs. National guidelines and direct-acting antivirals improve diagnosis and treatment access for HCV elimination.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Background:
- Hepatitis C virus (HCV) infection is a significant cause of liver disease and hepatocellular carcinoma in China.
- Injecting drug use is the primary route of HCV transmission, with an estimated prevalence of 0.91% in Mainland China.
Purpose of the Study:
- To review the current status and challenges of hepatitis C prevalence, diagnosis, and treatment in China.
- To align with the global goal of viral hepatitis elimination by 2030.
Main Methods:
- Analysis of national guidelines for HCV diagnosis and treatment.
- Review of in-hospital screening processes and risk group screening strategies.
- Assessment of the impact of direct-acting antivirals (DAAs) accessibility.
Main Results:
- National Medical Insurance now reimburses 3 DAAs, enhancing treatment accessibility.
- Chinese Medical Association guidelines standardize HCV screening, diagnosis, and management.
- Screening and treatment of at-risk populations are underway, contributing to reduced infection rates.
Conclusions:
- Standardized guidelines and improved access to direct-acting antivirals are crucial for hepatitis C control in China.
- Targeted screening and treatment of at-risk groups are essential for achieving hepatitis C micro-elimination.
- China's efforts are integral to the global strategy for viral hepatitis elimination by 2030.
Abstract:
Infection with the hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma in China. Rapid economic development has had an enormous impact on the epidemiology and treatment of hepatitis C. The prevalence of anti-HCV antibodies in Mainland China is approximately 0.91%, and use of injected drugs has become the main route of HCV transmission in China. Reimbursement for 3 direct-acting antivirals (DAAs) has been approved by the National Medical Insurance scheme in China, which ensures the accessibility of treatment for an HCV infection. To improve the awareness of treatments for hepatitis C among medical personnel and the rate of in-hospital screening for HCV, the Chinese Medical Association has formulated guidelines for the diagnosis and treatment of hepatitis C and a process of in-hospital screening for hepatitis C in China. These efforts have standardized the screening, diagnosis, treatment, and management of hepatitis C. Based on the international strategy for micro-elimination of hepatitis C, China has also screened and treated groups at risk of hepatitis C infection, and this has reduced the number of the infected. The current review describes the status of and issues with the prevalence, diagnosis, and treatment of hepatitis C in Mainland China as part of the global effort to eliminate viral hepatitis by 2030.
Related Concept Videos
01:25Hepatitis
01:28Viral Hepatitis I: Introduction